Kevin Dalby , Associate Professor of Pharmacy, Medicinal Chemistry
 
Cancer is most commonly caused by the development of aberrant cell signaling pathways. Modern pharmaceutical research thus seeks a clear understanding of these pathways in efforts to treat this all too prevalent illness. A major focus in our laboratory is ERK, a striking mitogen-activated protein kinase that regulates cellular processes with remarkable efficiency and specificity. MAP kinases are mediators of numerous cellular signals, and are believed to play major roles in tumor formation and progression to metastasis. The mitogenic pathway most important in the pathogenesis of human cancer contains the Ras–>Raf–>MEK–>ERK module. Students with an interest in integrating the disciplines of chemistry and biochemistry in the search for treatment of human disease are strongly encouraged to join us by applying. We employ a chemical-biology approach in efforts to elucidate the biochemical basis for the regulation and mechanism of protein kinases. Using state-of-the-art enzyme kinetic techniques we have uncovered surprising mechanisms of substrate recognition. We are currently applying structural methods to address some of the questions posed by these studies. Using high through-put screening, coupled to chemical and peptide library approaches, we are developing small molecule and peptide inhibitors of protein kinases. These inhibitors will be used to elucidate the roles of kinases in cancer progression. Soon, small-molecule inhibitor design will be complimented through virtual screening efforts. More recently, we have begun to develop new chemical-biology tools, in order to interrogate protein kinase pathways in living cells. Here, our mechanistic knowledge is crucial for the development of fluorescent sensors and inhibitors that will be delivered into living cells. The potential for cancer treatment through the targeting of protein kinase remains largely untapped. Our laboratory endeavors to identify these treatments by utilizing novel efforts in chemical biology.
Publications:
2007Brahma A, Dalby KN, Regulation of protein phosphorylation within the MKK1-ERK2 complex by MP1 and the MP1*P14 heterodimer, Arch Biochem Biophys 460, p.85-91
2007Abramczyk O, Rainey MA, Barnes R, Martin L, Dalby KN, Expanding the repertoire of an ERK2 recruitment site: cysteine footprinting identifies the D-recruitment site as a mediator of Ets-1 binding, Biochemistry 46, p.9174-9186
2007Callaway K, Abramczyk O, Martin L, Dalby KN, The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site, Biochemistry 46, p.9187-9198
2006Callaway KA, Rainey MA, Riggs AF, Abramczyk O, Dalby KN, Properties and regulation of a transiently assembled ERK2.Ets-1 signaling complex, Biochemistry 45, p.13719-13733

 
Chemical Biology and Drug Discovery Tracks and Research Focus Areas
 
Aldrich, RichardAnslyn, Eric V.Appling, Dean
Bajaj, ChandrajitBratton, ShawnBull, James J.
Dalby, KevinEllington, AndyFast, Walter
Georgiou, GeorgeGottlieb, EllenHackert, Marvin
Iverson, BrentJohnson, KennethKerwin, Sean
Kitto, G. BarrieKline, KimberlyKrug, Robert
Lambowitz, Alan M.Lane, MichelleLee, Seongmin
Liu, Hung-wen (Ben)Mahal, LaraMarcotte, Edward
Martin, StephenMaynard, JenniferMcDevitt, John
Poenie, MartinRen, PengyuRichburg, John
Robertus, JonRoy, KrishnenduSanders, Bob
Shear, JasonSuggs, LauraTrent , M. Stephen
Whitman, ChristianWright, CaseyZhang, Zhiwen (Jonathan)

 CMB Graduate Program